Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer

NCT01298713 | Completed Phase 2

• 2 other identifiers: TAMRADEUDRACT 2006-004332-79
• Study Type: interventional
• Target: 111
• Locations: 1 country
• Sites: 1

Brief Summary

Tamoxifen is a classical treatment for breast metastatic cancer after 3rd generation anti-aromatase hormonotherapy in adjuvant or in metastatic line. The Tamoxifen efficacy is lowered by the hormonoresistance mechanisms due to the primary use of the anti-aromatases. The Pi3K-AKT-mTor pathway is frequently associated to the hormonoresistance mechanisms. This study is aimed to check if the inhibition of this signal transduction pathway by a synthetic mTor inhibitor (Everolimus) could improve the efficacy of the Tamoxifen.

Conditions

Breast Neoplasms; mTor Protein

Keywords

Hormonoresistance; tamoxifen; Previously received anti-aromatase treatment; mTor inhibitor

Outcome Measures

Primary Outcomes (1)

• Clinical benefit at 24 weeks

  42 months

Secondary Outcomes (3)

• Partial and complete response per RECIST

  42 months

• Qualitative and quantitative toxicities

  24 months

• Overall survival

  42 months

Study Arms (2)

A

ACTIVE COMPARATOR

Tamoxifen 20mg/d

Drug: Tamoxifen

B

EXPERIMENTAL

Tamoxifen 20mg/d + RAD001 10mg/d

Drug: Tamoxifen; Drug: Everolimus

Interventions

Tamoxifen DRUG

20mg daily (1 cap) until unbearable toxicity or progression

A; B

Everolimus DRUG

10mg daily (2 caps of 5mg) until unbearable toxicity or progression

Also known as: RAD001

B

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Menopausal female patient aged \> 18 years
• Histologically proven breast adenocarcinoma
• ER and/or PR positive receptors and HER2 negative
• previously received first or second line of hormonotherapy for metastatic disease
• previously treated with anti-aromatase in adjuvant and/or in metastatic line
• presence of one or several mesurable or evaluable metastatic lesion(s)
• presence of at least one target lesion not previously irradiated
• ECOG Performance status \< 2
• adequate biological values
• patient who has clearly given her consent by signing on informed consent form prior to participation

You may not qualify if:

• patient with only local metastatic disease that can be treted by surgery
• uncotrolled brain metastases, pulmonary carcinomatosal lymphangitis, hepatic metastases
• Previous treatment by Tamoxifen unless in adjuvant and terminated more than a year before metastatic relapse
• Patient with a tumor surexpressing HER2 that should be treated by trastuzumab
• Patient that need an immediate local antalgic radiotherapy
• Thrombo-embolism disease
• serious concomitant pathology or uncontrolled that is susceptible to compromise the participation in the study
• history of another malignancy within past 5 years that could confound diagnosis or staging of breast cancer (with the exception of in situ cacinoma of the cervix or adequately treated basel cell carcinoma of the skin) and cancers cured for at least for 5 years
• patient with an history of significant cardiovascular impairment (congestive heart failure\> NYHA grade II, unstable angina or myocardial infraction within the past six months or serious cardiac arrhythmia)
• patient with any medical or psychiatric condition that, in the opinion of the Principal Investigator, would preclude her from participating in this study
• patient with a known allergy to one or several of the study compounds
• patients who may not be regularly available due to geographical, social or family reasons
• history of renal, hepatic or metabolic pathology that could preclude with metabolism or elimination of the study product
• deficiencies of the upper intestinal tract, malabsorption syndrome
• patient who is pregnant, breast-feeding or using inadequate contraception

Sponsors & Collaborators

• ARCAGY/ GINECO GROUP: lead
• Novartis: collaborator

Study Sites (1)

Hopital Hotel Dieu

Paris, 75004, France

Location

Related Publications (1)

• Treilleux I, Arnedos M, Cropet C, Wang Q, Ferrero JM, Abadie-Lacourtoisie S, Levy C, Legouffe E, Lortholary A, Pujade-Lauraine E, Bourcier AV, Eymard JC, Spaeth D, Bachelot T. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. Ann Oncol. 2015 Jan;26(1):120-125. doi: 10.1093/annonc/mdu497. Epub 2014 Oct 31.

  PMID: 25361980 DERIVED

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Tamoxifen; Everolimus

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Stilbenes; Benzylidene Compounds; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Sirolimus; Macrolides; Lactones

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 16, 2011
• First Posted: February 18, 2011
• Study Start: March 1, 2008
• Primary Completion: June 1, 2011
• Study Completion: September 12, 2018
• Last Updated: September 6, 2023

Record last verified: 2023-09

Locations

FR (1)